Oncotarget


Please enjoy our recent Announcements and Press Releases

Announcements

On June 25, 2022 – Impact Journals (Oncotarget's publisher) is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, New York. Learn more.

June 1–3, 2022 – Impact Journals (Oncotarget's publisher) is a supporter and exhibitor at the Society for Scholarly Publishing (SSP) 44th Annual Meeting. We will be presenting our full scientific integrity process at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois. Learn more.

On March 28, 2022 – Impact Journals publishes scholarly journals in biomedical sciences with a focus on all areas of cancer and aging research. Impact Journals is participating as an exhibitor at the American Association for Cancer Research (AACR) 2022 annual meeting from April 8-13, 2022, in New Orleans, Louisiana. This year, the AACR conference is entitled, “Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.”

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

On September 23, 2021, Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) launched a new web page showcasing the full Oncotarget Scientific Integrity Process.

Read about it in greater detail on Oncotarget’s new Scientific Integrity web page.

The new page also showcasts a visual representation of the number of post-publication corrections and retractions by Oncotarget compared to the industry average between 2010 and 2021. As of September 23, 2021, Oncotarget’s rate of corrections/retractions is 2.87%. The industry average correction/retraction rate is 3.80%.


Oncotarget | New Oncology-Focused Papers Published in Volume 13


FOR IMMEDIATE RELEASE
2022-06-23

As of June 23, 2022, Oncotarget has published a total of 64 high-impact, oncology-focused papers within Volume 13.



BUFFALO, NY- June 23, 2022 –
At the start of 2022, Oncotarget began publishing research papers in a continuous publishing format in yearly volumes. As of June 23, 2022, Oncotarget has published a total of 64 high-impact, oncology-focused papers within Volume 13. Oncotarget’s Volume 13 consists of papers authored by numerous prestigious researchers and scientists from world-renowned
... continue reading >>



Oncotarget | Impact Journals Sponsors 2022 Ride for Roswell


FOR IMMEDIATE RELEASE
2022-06-14

Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.

BUFFALO, NY- June 14, 2022 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 26 years to celebrate cancer survivors, pay tribute to lives that... continue reading >>



Oncotarget | A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis


FOR IMMEDIATE RELEASE
2022-06-08

“Our findings identify 34 novel genes for further study as potential therapeutic targets for treatment of endocrine-resistant BC and TNBC.”


BUFFALO, NY- June 8, 2022 –
A research paper was recently published in Oncotarget, entitled, “A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.”
 

Breast cancer (BC) is the most common type of cancer diagnosed in women. Among female cancer deaths, BC is the second leading cause of death... continue reading >>




Copyright © 2022 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC